Lonza, Takeda reach regulatory milestone in oncology tie-up

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Oatawa)
(Image: Getty/Oatawa)

Related tags: Oncology, Clinical development, Packaging, Supply chain, Supply chain management, marketing authorization, Marketing

Lonza provided development, manufacturing, and clinical packaging services for Takeda’s Alunbrig, which has received EMA marketing authorization.

Alunbrig (brigatinib), indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC), received marketing authorization by the European Medicines Agency (EMA).

Ben Sahacic, director of commercial development at Lonza told us, “Lonza provided validation and regulatory submission support with Takeda leveraging benefits of a simplified supply chain with development, manufacturing, and clinical packaging in a single location in Tampa, Florida for both US and EU submissions.”

Lonza’s FL-based facility provided services for both US and EU submissions. Additionally, it produced clinical material for Phase I, II and II studies.

“Lonza will provide ongoing manufacturing product-resupply activities for brigatinib, while, in parallel, engaging in assessment of further collaboration on new oncology programs,”​ Sahacic stated.

According to Sahacic, Takeda is a “strategic client”​ for the advancement of oncology platforms for both clinical and commercial settings. 

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars